SCP
SCMP

Seizert Capital Partners’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Seizert Capital Partners’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-131,703
Closed -$1.45M – 221
2017
Q1 		$1.45M Buy
+131,703
New +$1.53M 0.05% 131

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Seizert Capital Partners's SCMP Position: Q2 2017 in Review

Seizert Capital Partners sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q2 2017, closing a stake of 131,703 shares — an estimated $1.45M sold.

Seizert Capital Partners first reported a position in SCMP in Q1 2017 and held it in 1 quarter. The position peaked at $1.45M in Q1 2017. 167 funds tracked by Wall St. Rank hold SCMP as of Q2 2017.

  • Seizert Capital Partners reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Seizert Capital Partners sold 131,703 Sucampo Pharmaceuticals, Inc. shares in Q2 2017, an estimated $1.45M.
  • Seizert Capital Partners first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2017 and held it in 1 quarter.
  • Seizert Capital Partners's Sucampo Pharmaceuticals, Inc. position peaked at $1.45M in Q1 2017.
  • 167 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q2 2017.

Based on Seizert Capital Partners's 13F filing for Q2 2017, filed 9 Aug 2017.